Research programme: gene therapies - Spark Therapeutics

Drug Profile

Research programme: gene therapies - Spark Therapeutics

Latest Information Update: 15 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator The Childrens Hospital of Philadelphia
  • Developer Spark Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological disorders; Neurodegenerative disorders; Retinal disorders

Most Recent Events

  • 28 Apr 2015 Spark Therapeutics enters into an option agreement with Clearside Biomedical for exclusive licensing rights for the micoinjector technology for delivering gene therapies to the back of the eye
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top